Abstract:
The present invention provides a compound of general formulae A useful as potential anti-cancer agents against human cancer cell lines and a process for the preparation thereof. Where in R, R 1 , R 2 ═H, alkyl, alkoxy, halo, haloalkyl, halomethoxy, nitro and G= 
     
       
                 
         
             
             
         
       
     
     Where in R, R 1 , R 2 ═H, alkyl, alkoxy, halo, haloalkyl, halomethoxy, nitro and G=

Description:
FIELD OF THE INVENTION 
       [0001]    The present invention relates to amidobenzothiazoles of general formula A 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein R, R 1 , R 2 ═H, alkoxy, halo, haloalkyl, halomethyl or nitro and 
       G= 
       [0002]    
       
                 
         
             
             
         
       
     
         [0000]    and structural formula of the representative compounds are: 
         [0000]    
       
                 
         
             
             
         
       
     
         [0003]    Present invention further relates to amidobenzothiazoles of general formula A as anticancer agents and process for the preparation thereof. 
         [0004]    Present invention further relates to olefine, chalcone, pyrazoline, pyrazole, isoxazoline and isoxazoles linked to aminobenzothiazoles with amide bond useful as anticancer agents. 
       BACKGROUND OF THE INVENTION 
       [0005]    Inhibition of tubulin polymerization is the target of many antitumoural agents known as antimitotic agents or spindle poisons colchicines, podophyllotoxins and combretastatins are representative examples of compounds that inhibit microtubule assembly by binding to tubulin. Benzothiazoles are small synthetic molecules that contain a benzene ring fused to a thiazole ring. These simple molecules have shown remarkable anti-cancer properties and some of them are undergoing, evaluation in clinical trials (Shi, D.-F.; Bradshaw, T. D.; Wrigley, S.; McCall, C. J.; Lelieveld, P.; Fichtner, I.; Stevens, M. F. G.  J. Med. Chem.  1996, 39, 3375; Kashiyama, E.; Hutchinson, I.; Chua, M.-S.; Stinson, S. F.; Phillips, L. R.; Kaur, G.; Sausville, E. A.; Bradshaw, T. D.; Westwell, A. D.; Stevens, M. F. G.  J. Med. Chem.  1999, 42, 4172; Hutchinson, I.; Chua, M.-S.; Browne, H. L.; Trapani, V.; Bradshaw, T. D.; Westwell, A. D.; Stevens, M. F. G.  J. Med. Chem.  2001, 44, 1446). Recently Westwell and coworkers have prepared a series of benzothiazole derivatives and evaluated for anticancer activity, One of these analogues has shown excellent anticancer activity (Mortimer, C. G.; Wells, G.; Crochard, J.-P.; Stone, E. L.; Bradshaw, T. D.; Stevens, M. F. G.; Westwell, A. D.  J. Med. Chem.  2006, 49, 179). Many chalcone, pyrazoline, isoxazole and isoxazoline type moieties related to combretastain A-4 showed potential biological properties particularly anticancer activity (Sylvie Ducki, David Rennison, Meiko Woo, Alexander Kendall, Jérémie Fournier Dit Chabert, Alan T. McGown, Nicholas J. Lawrence.  Bioorg. Med. Chem , Vol 17, 22, 2009, 7698-7710; Regan LeBlanc, John Dickson, Toni Brown, Michelle Stewart, Hari N. Pati, Don VanDerveer, Hadi Arman, Jeff Harris, William Pennington, Herman L. Holt Jr., Moses Lee.  Bioorg. Med. Chem , Volume 13, 21, 2005, 6025-6034; Marlie Johnson, Brent Younglove, Lauren Lee, Regan LeBlanc, Herman Holt Jr., Patrice Hills, Hilary Mackay, Toni Brown, Susan L. Mooberry, Moses Lee.  Bioorg. Med. Chem Lett , Vol 17, 21, 2007, 5897-5901; B. A. Bhat, K. L. Dhar, S. C. Puri, A. K. Saxena, M. Shanmugavel, G. N. Qazi.  Bioorg. Med. Chem Lett , Vol 15, 12, 2005, 3177-3180; Simoni, D.; Grisolia, G.; Giannini, G.; Roberti, M.; Rondanin, R.; Piccagli, L.; Baruchello, R.; Rossi, M.; Romagnoli, R.; Invidiata, F. P.; Grimaudo, S.; Jung, M. K.; Hamel, E.; Gebbia, N.; Crosta, L.; Abbadessa, V.; DiCristina, A.; Dusonchet, L.; Meli, M.; Tolomeo, M. J. Med. Chem. 2005, 48, 723, Julia Kaffy, a Rene&#39;e Pontikis, a, Danie&#39;le Carrez, b Alain Croisy, Claude Monnereta and Jean-Claude Florent. Bioorg. Med. Chem. 2006, 14, 4067-4077, Gian Ceasure Tron, Tracy Pirali, Giovanni sorba, Francesca pagliai, Sara Buasacca and Armado A. Genazzani. J. Med. Chem. 2006, 49, 3033-3044. and Tracey Pirali, Sara buasacca, Lorena Beltrami, Daniela Imovilli, Francesca Paliai, Gianluca Migilio, Alberto Massrotti, Luisella Verotta, Gian Cesare Tron, Givanni Sorba, and Armado A. Genazzani. J. Med. Chem. 2006, 49, 5372-5376). Some of the heterocyclic bridged Combretastains showed an attractive profile of cytotoxicity and were able to induce apoptosis at lower concentrations. 
         [0000]    
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
     
       OBJECTIVE OF THE INVENTION 
       [0006]    The main objective of the present invention is to provide amidobenzothiazole of general formula A useful as anti-cancer agents. 
         [0007]    Yet another object of the present invention is to provide a process for the preparation of amidobenzothiazole of general formula A. 
       SUMMARY OF THE INVENTION 
       [0008]    Accordingly, present invention relates to amidobenzothiazole of general formula A 
         [0000]    
       
                 
         
             
             
         
       
     
         [0000]    wherein R, R 1 , R 2 ═H, alkoxy, halo, haloalkyl, halomethyl or nitro and 
       G= 
       [0009]    
       
                 
         
             
             
         
       
     
         [0010]    In an embodiment of the present invention, chemical formulas of the representative compounds are:
   N1-(1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8a);   N1-(6-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8b);   N1-(6-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8e);   N1-(6-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8d);   N1-(6-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8e);   N1-(6-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8f);   N1-(6-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8g);   N1-(6-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8h);   N1-(6-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8i);   N1-(6-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8j);   N1-(4-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8k);   N1-(5-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8l);   N1-(5-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8m);   N1-(5-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8n);   N1-(5-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8o);   N1-(5-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8p);   N1-(5-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8q);   N1-(5-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8r);   N1-(5-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8s);   N1-(5-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8t);   N1-(5,6-dimethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8u);   N1-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8v);   N1-(1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9a);   N1-(6-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9b);   N1-(6-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9c);   N1-(6-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9d);   N1-(6-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9e);   N1-(6-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9i);   N1-(6-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9g);   N1-(6-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9h);   N1-(6-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9i);   N1-(6-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9j);   N1-(4-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9k);   N1-(5-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9l);   N1-(5-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9m);   N1-(5-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9n);   N1-(5-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9o);   N1-(5-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9p);   N1-(5-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9q);   N1-(5-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9r);   N1-(5-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9s);   N1-(5-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9t);   N1-(5,6-dimethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9u);   N1-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9v);   N1-(1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10a);   N1-(6-nitro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10b);   N1-(6-methyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10c);   N1-(6-ethyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10d);   N1-(6-fluoro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10e);   N1-(6-chloro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10f);   N1-(6-methoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10g);   N1-(6-ethoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10h);   N1-(6-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10i);   N1-(6-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxy phenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10j);   N1-(4-methyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10k);   N1-(5-nitro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10l);   N1-(5-methyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10m);   N1-(5-ethyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10n);   N1-(5-fluoro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10o);   N1-(5-chloro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10p);   N1-(5-methoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10q);   N1-(5-ethoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10r);   N1-(5-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10s);   N1-(5-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10t);   N1-(5,6-dimethyl-1,3-benzothiazol-2-yl)-2-5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxyacetamide (10u);   N1-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxyacetamide (10v);   N1-(1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11a);   N1-(6-nitro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11b);   N1-(6-methyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11c);   N1-(6-ethyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11d);   N1-(6-fluoro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11e);   N1-(6-chloro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11f);   N1-(6-methoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11g);   N1-(6-ethoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11h);   N1-(6-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxy phenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11i);   N1-(6-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxy phenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11j);   N1-(4-methyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11k);   N1-(5-nitro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11l);   N1-(5-methyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11m);   N1-(5-ethyl-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11n);   N1-(5-fluoro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11o);   N1-(5-chloro-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11p);   N1-(5-methoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11q);   N1-(5-ethoxy-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11r);   N1-(5-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxy phenyl-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11s);   N1-(5-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxy phenyl)-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (11t);   N1-(5,6-dimethyl-1,3-benzothiazol-2-yl)-2-5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxyacetamide (11u);   N1-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-1H-5-pyrazolyl]-2-methoxyphenoxyacetamide (11v);   N1-(1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12a);   N1-(6-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12b);   N1-(6-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12c);   N1-(6-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12d);   N1-(6-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12e);   N1-(6-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12f);   N1-(6-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12g);   N1-(6-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12h);   N1-(6-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-Methoxy-5-[3-(3,4,5-trimethoxy phenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12i);   N1-(6-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxy phenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12j);   N1-(4-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12k);   N1-(5-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12l);   N1-(5-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12m);   N1-(5-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12n);   N1-(5-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12o);   N1-(5-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12p);   N1-(5-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12q);   N1-(5-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12r);   N1-(5-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxy phenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12s);   N1-(5-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxy phenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12t);   N1-(5,6-dimethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12u);   N1-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-5-isoxazolyl]-2-methoxyphenoxy}acetamide (12v);   N1-(1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13a);   N1-(6-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13b);   N1-(6-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13e);   N1-(6-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13d);   N1-(6-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13e);   N1-(6-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13f);   N1-(6-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13g);   N1-(6-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13h);   N1-(6-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxy phenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13i);   N1-(6-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxy phenyl-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13j);   N1-(4-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13k);   N1-(5-nitro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13l);   N1-(5-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13m);   N1-(5-ethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13n);   N1-(5-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13o);   N1-(5-chloro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13p);   N1-(5-methoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13q);   N1-(5-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13r);   N1-(5-(trifluoromethyl)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxy phenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13s);   N1-(5-(trifluoromethoxy)-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxy phenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13t);   N1-(5,6-dimethyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13u);   N1-(5,6-difluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-5-isoxazolyl]-2-methoxyphenoxy}acetamide (13v).   
 
         [0000]    
       
         
               
             
               
               
               
             
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 1 
               
             
             
               
                   
               
               
                 Showing the amidobenzothiazoles formed by reacting 
               
               
                 compounds 7(a-v) with compounds 1-6: 
               
             
          
           
               
                   
                 Comp. No. 
                   
               
             
          
           
               
                   
                 7(a-v)/1-6 
                 1 
                 2 
                 3 
                 4 
                 5 
                 6 
               
               
                   
                   
               
               
                   
                 7a 
                 8a 
                 9a 
                 10a 
                 11a 
                 12a 
                 13a 
               
               
                   
                 7b 
                 8b 
                 9b 
                 10b 
                 11b 
                 12b 
                 13b 
               
               
                   
                 7c 
                 8c 
                 9c 
                 10c 
                 11c 
                 12c 
                 13c 
               
               
                   
                 7d 
                 8d 
                 9d 
                 10d 
                 11d 
                 12d 
                 13d 
               
               
                   
                 7e 
                 8e 
                 9e 
                 10e 
                 11e 
                 12e 
                 13e 
               
               
                   
                 7f 
                 8f 
                 9f 
                 10f 
                 11f 
                 12f 
                 13f 
               
               
                   
                 7g 
                 8g 
                 9g 
                 10g 
                 11g 
                 12g 
                 13g 
               
               
                   
                 7h 
                 8h 
                 9h 
                 10h 
                 11h 
                 12h 
                 13h 
               
               
                   
                 7i 
                 8i 
                 9i 
                 10i 
                 11i 
                 12i 
                 13i 
               
               
                   
                 7j 
                 8j 
                 9j 
                 10j 
                 11j 
                 12j 
                 13j 
               
               
                   
                 7k 
                 8k 
                 9k 
                 10k 
                 11k 
                 12k 
                 13k 
               
               
                   
                 7l 
                 8l 
                 9l 
                 10l 
                 11l 
                 12l 
                 13l 
               
               
                   
                 7m 
                 8m 
                 9m 
                 10m 
                 11m 
                 12m 
                 13m 
               
               
                   
                 7n 
                 8n 
                 9n 
                 10n 
                 11n 
                 12n 
                 13n 
               
               
                   
                 7o 
                 8o 
                 9o 
                 10o 
                 11o 
                 12o 
                 13o 
               
               
                   
                 7p 
                 8p 
                 9p 
                 10p 
                 11p 
                 12p 
                 13p 
               
               
                   
                 7q 
                 8q 
                 9q 
                 10q 
                 11q 
                 12q 
                 13q 
               
               
                   
                 7r 
                 8r 
                 9r 
                 10r 
                 11r 
                 12r 
                 13r 
               
               
                   
                 7s 
                 8s 
                 9s 
                 10s 
                 11s 
                 12s 
                 13s 
               
               
                   
                 7t 
                 8t 
                 9t 
                 10t 
                 11t 
                 12t 
                 13t 
               
               
                   
                 7u 
                 8u 
                 9u 
                 10u 
                 11u 
                 12u 
                 13u 
               
               
                   
                 7v 
                 8v 
                 9v 
                 10v 
                 11v 
                 12v 
                 13v 
               
               
                   
                   
               
             
          
         
       
     
         [0143]    In yet another embodiment of the present invention, structural formulas of the representative compounds 8-13 (a-v) are: 
         [0000]    
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
       
                 
         
             
             
         
       
     
         [0144]    In yet another embodiment of the present invention, said compounds are useful as anti-cancer agents. 
         [0145]    In yet another embodiment of the present invention, said compounds exhibit an in vitro anticancer activity against human cancer cell lines selected from the group consisting of leukemia cancer cell lines, non-small cell lung cancer cell lines, colon cancer cell lines, CNS cancer cell lines, melanoma cancer cell lines, ovarian cancer cell lines, renal cancer cell lines, prostate cancer cell lines and breast cancer cell lines. 
         [0146]    In yet another embodiment of the present invention, process for the preparation of amidobenzothiazole of general formula A comprising the steps of:
       i. reacting 2-aminobenzothiazoles of formula 7a-v with a compound selected from formulae 1, 2, 3, 4, 5 and 6 in an organic solvent in the presence of EDC (1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide) and 1-hydroxy-1,2,3-benzotriazole(HOBt) at a temperature in the range of 25 to 30° C. for a period in the range of 22 to 24 hrs;       
 
         [0000]    
       
                 
         
             
             
         
       
       
         
           
             ii. adding water in the mixture as obtained in step (i) and extracting with organic solvent and evaporating the organic solvent to obtain the resultant crude product; 
             iii. purifying crude product as obtained in step (ii) by column chromatography to obtain the desired products of formulae 8a-v, 9a-v, 10a-v, 11a-v, 12a-v and 13a-v. 
           
         
       
     
         [0150]    In yet another embodiment of the present invention, organic solvent used is selected from the group consisting of dichloromethane, chloroform or N,N-dimethylformamide. 
         [0151]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i) used for in vitro activity against leukemia cancer cell lines is in the range of 0.037 to 29.9 μM. 
         [0152]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8a, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i) used for in vitro activity against non small cell lung cancer cell lines is in the range of 0.038 to 50.3 μM. 
         [0153]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i) used for in vitro activity against colon cancer cell lines is in the range of 0.046 to 94.8 μM. 
         [0154]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i) used for in vitro activity against CNS cancer cell lines is in the range of 0.045 to 18.8 μM. 
         [0155]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8a, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i) used for in vitro activity against melanoma cancer cell lines is in the range of 0.019 to 89.2 μM. 
         [0156]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g; 9i, 9j and 10i) used for in vitro activity against ovarian cancer cell lines is in the range of 0.033 to 91.6 μM. 
         [0157]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i) used for in vitro activity against renal cancer cell lines is in the range of 0.05 to 100 μM. 
         [0158]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i) used for in vitro activity against prostate cancer cell lines is in the range of 0.18 to 22.9 μM. 
         [0159]    In yet another embodiment of the present invention, GI50 values of the compounds (8a, 8e, 8g, 8i, 8j, 9a, 9e, 9a, 9i, 9j and 10i) used for in vitro activity against breast cancer cell lines is in the range of 0.051 to 58.5 μM. 
       BRIEF DESCRIPTION OF THE DRAWINGS 
       [0160]    Scheme 1 represents the flow diagram for the preparation of compound 1. Wherein reagent and conditions are i) TBDMS-Cl, TEA, DMF; ii) NaBH 4 , MeOH; iii) LiBr, THF; iv) PPH 3 , toluene; v) n-BuLi, THF, −20° C., trimethoxy benzaldehyde; vi) TBAF, THF; vii) 2-bromoethyl acetate, K 2 CO 3 , DMF; viii) LiOH, THF, H 2 O 
         [0161]    Scheme 2 represents the flow diagram for the preparation of compound 2. 
         [0162]    Scheme 3 represents the flow diagram for the preparation of compound 3. 
         [0163]    Scheme 4 represents the flow diagram for the preparation of compound 4. 
         [0164]    Scheme 5 represents the flow diagram for the preparation of compound 5. Wherein reagent and conditions are i) NH 2 OH.HCl, NaHCO 3 , H 2 O ii) CH 3 P(Ph) 3   + Br − , KOtBu, THF; iii) NaOCl, Et 3 N, DCM; iv) TBAF, THF; v) 2-bromoethyl acetate, K 2 CO 3 , DMF; vi) THF, H 2 O 
         [0165]    Scheme 6 represents the flow diagram for the preparation of compound 6. Wherein reagent and conditions are i) NH 2 OH.HCl, NaHCO 3 , CH 3 OH, H 2 O ii) CBr 4 , PPh 3 , DCM; iii) n-BuLi, THF, −78° C.; iii) NaOCl, Et 3 N, DCM; iv) TBAF, THF; v) 2-bromoethyl acetate, K 2 CO 3 , DMF; vi) LiOH, THF, H 2 O. 
         [0166]    Scheme 7 represents the flow diagram for the preparation of compound 8-13(a-v). 
     
    
     DETAILED DESCRIPTION OF THE INVENTION 
       [0167]    The precursors 2-aminobenzothiazoles of formula 7a-v are commercially available and the precursors combretastatin, chalcone, pyrazoline, pyrazole, isoxazoline and isoxazole of formulae 1, 2, 3, 4, 5 and 6 have been prepared using literature methods or as shown in schemes (Sylvie Ducki, David Rennison, Meiko Woo, Alexander Kendall, Jérémie Fournier Dit Chabert, Alan T. McGown, Nicholas J. Lawrence.  Bioorg. Med. Chem , Vol 17, 22, 2009, 7698-7710; Regan LeBlanc, John Dickson, Toni Brown, Michelle Stewart, Hari N. Pati, Don VanDerveer, Hadi Arman, Jeff Harris, William Pennington, Herman L. Holt Jr., Moses Lee.  Bioorg. Med. Chem , Volume 13, 21, 2005, 6025-6034; Marlie Johnson, Brent Younglove, Lauren Lee, Regan LeBlanc, Herman Holt Jr., Patrice Hills, Hilary Mackay, Toni Brown, Susan L. Mooberry, Moses Lee.  Bioorg. Med. Chem Lett , Vol 17, 21, 2007, 5897-5901; B. A. Bhat, K. L. Dhar, S. C. Puri, A. K. Saxena, M. Shanmugavel, G. N. Qazi.  Bioorg. Med. Chem Lett , Vol 15, 12, 2005, 3177-3180; Gian Ceasure Tron, Tracy Pirali, Giovanni sorba, Francesca pagliai, Sara Buasacca and Armado A. Genazzani. J. Med. Chem. 2006, 49, 3033-3044. and Tracey Pirali, Sara buasacca, Lorena Beltrami, Daniela Imovilli, Francesca Paliai, Gianluca Migilio, Alberto Massrotti, Luisella Verotta, Gian Cesare Tron, Givanni Sorba, and Armado A. Genazzani. J. Med. Chem. 2006, 49, 5372-5376; Julia kaffy, Renee Pontikis, Daniele Carrez, Alain Croisy, Claude Monneret and Jean-Claude Florent. Bioorg. Med. Chem. 2006, 14, 4067-4077, Simoni, D.; Grisolia, G.; Giannini, G.; Roberti, M.; Rondanin, R.; Piccagli, L.; Baruchello, R.; Rossi, M.; Romagnoli, R.; Invidiata, F. P.; Grimaudo, S.; Jung, M. K.; Hamel, E.; Gebbia, N.; Crosta, L.; Abbadessa, V.; DiCristina, A.; Dusonchet, L.; Meli, M.; Tolomeo, M. J. Med. Chem. 2005, 48, 723). 
         [0168]    These new analogues of olefine, chalcone, pyrazoline, pyrazole, isoxazole and isoxazoline linked amidobenzothiazole have shown promising anticancer activity in various cancer cell lines. The molecules synthesized are of immense biological significance. 
       EXAMPLES 
       [0169]    The following examples are given by way of illustration and therefore should not be construed to the present limit of the scope of invention. 
       Example 1 
     N1-(1,3-Benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8a) 
       [0170]    To a solution of 2-aminobenzothiazole (150 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetic acid (1) (374 mg, 1.0 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (8a) (395 mg, 80% yield). 
         [0171]      1 H NMR (CDCl 3 ): δ7.74-7.82 (m, 2H), 7.37-7.44 (m, 1H), 7.29 (d, 1H, J=8.3 Hz), 6.96-7.01 (d, 1H, J=8.3, 2.2 Hz), 6.93 (d, 1H, J=2.2 Hz), 6.82 (d, 1H, J=8.3 Hz), 6.46 (d, 1H, J=12.0 Hz), 6.38-4.30 (m, 3H), 4.60 (s, 2H), 4.02 (s, 3H), 3.83 (s, 3H), 3.69 (s, 6H); ESIMS: 507 (M+1) + . 
       Example 2 
     N1-(6-fluoro-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetamide (8e) 
       [0172]    To a solution of 6-fluoro-2-aminobenzothiazole (168 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetic acid(1) (374 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using, ethyl acetate and hexane as solvent system to obtain the pure product (8e) (375 mg, 70% yield). 
         [0173]      1 H NMR (CDCl 3 ): δ 7.71-7.76 (m, 1H), 7.47-7.53 (dd, 1H, J=8.1, 2.4 Hz), 7.13-7.20 (m, 1H), 7.00-7.04 (dd, 1H, J=8.1, 1.6 Hz), 6.93 (d, 1H, J=1.6 Hz), 6.83 (d, 1H, J=8.1 Hz), 6.46-6.51 (m, 3H), 6.44 (d, 1H, J=12.2 Hz), 4.63 (s, 2H), 3.98 (s, 3H), 3.85 (s, 3H), 3.70 (s, 6H); ESIMS: 525 (M+1) + . 
       Example 3 
     N1-[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxy phenyl)-1-ethenyl]phenoxy}acetamide (8i) 
       [0174]    To a solution of 6-(trifluoromethyl)-2-aminobenzothiazole (218 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetic ac id (1) (374 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (8i) (450 mg, 80% yield) 
         [0175]      1 H NMR (CDCl 3 ): δ 8.12 (s, 1H), 7.93 (d, 1H, J=8.4 Hz), 7.69-7.75 (m, 1H), 7.01-7.06 (dd, 1H, J=8.3, 1.7 Hz), 6.95 (d, 1H, J=1.7 Hz), 6.85 (d, 1H, J=8.3 Hz), 6.43-6.53 (m, 1H), 4.68 (s, 2H), 3.99 (s, 3H), 3.83 (s, 3H), 3.70 (s, 6H); ESIMS: 575 (M+1) + . 
       Example 4 
     N1-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxy phenyl)-1-ethenyl]phenoxy}acetamide (8j) 
       [0176]    To a solution of 6-(trifluoromethoxy)-2-aminobenzothiazole (234 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(Z)-2-(3,4,5-trimethoxyphenyl)-1-ethenyl]phenoxy}acetic acid (1) (374 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (8j) (470 mg, 80% yield) 
         [0177]      1 H NMR (CDCl 3 ): δ 7.80 (d, 1H, J=8.8 Hz), 7.69 (s, 1H), 7.29-7.36 (dd, 1H, J=8.4, 2.2 Hz), 7.01-7.06 (dd, 1H, J=8.4, 1.7 Hz), 6.95 (d, 1H, J=1.7 Hz), 6.85 (d, 1H, J=8.3 Hz), 6.42-6.53 (m, 4H), 4.65 (s, 2H), 3.99 (s, 3H), 3.85 (s, 3H), 3.70 (s, 6H); ESIMS: 591 (M+1) +   
       Example 5 
     N1-(4-methyl-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxy phenyl)-1-propenyl]phenoxy}acetamide (9k) 
       [0178]    To a solution of 4-methyl-2-aminobenzothiazole (164 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxy phenyl)-1-propenyl]phenoxy}acetic acid (2) (402 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (9k) (440 mg, 80% yield) 
         [0179]      1 H NMR (CDCl 3 ): δ 10.71 (br s, 1H), 7.76 (d, 1H, J=15.4 Hz), 7.65-7.70 (m, 1H), 7.32-7.43 (m, 4H), 7.28 (s, 2H), 7.22-7.26 (m, 1H), 7.02 (d, 1H, J=8.4 Hz), 4.86 (s, 2H), 4.09 (s, 3H), 3.96 (s, 6H), 3.94 (s, 3H), 2.67 (s, 3H); ESIMS: 549 (M+1) + . 
       Example 6 
     N1-(6-ethoxy-1,3-benzothiazol-2-yl)-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxy phenyl)-1-propenyl]phenoxy}acetamide (9h) 
       [0180]    To a solution of 6-ethoxy-2-aminobenzothiazole (194 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxy phenyl)-1-propenyl]phenoxy}acetic acid (2) (402 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (9h) (452 mg, 80% yield). 
         [0181]      1 H NMR (CDCl 3 ): δ 7.75 (d, 1H, J=15.8 Hz), 7.70 (d, 1H, J=9.0 Hz), 7.36-7.41 (m, 2H), 7.29-7.34 (m, 2H), 7.25-7.28 (m, 3H), 7.01 (d, 1H, J=8.3 Hz), 4.84 (s, 2H), 4.06-4.15 (q, 2H), 4.04 (s, 3H), 3.96 (s, 6H), 3.95 (s, 3H), 1.46 (t, 3H); ESIMS: 565 (M+1) + . 
       Example 7 
     N1-[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9i) 
       [0182]    To a solution of 6-(trifluoromethyl)-2-aminobenzothiazole (218 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxy phenyl)-1-propenyl]phenoxy}acetic acid (2) (402 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (9i) (480 mg, 80% yield) 
         [0183]      1 H NMR (CDCl 3 ): δ 10.74 (br s, 1H), 8.11 (s, 1H), 7.87 (d, 1H, J=8.3 Hz), 7.64-7.74 (m, 2H), 7.28-7.40 (m, 3H), 7.22 (s, 2H), 6.99 (d, 1H, J=8.3 Hz), 4.84 (s, 2H), 4.09 (s, 3H), 3.95 (s, 6H), 3.91 (s, 3H); ESIMS: 603 (M+1) + . 
       Example 8 
     N1-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-2-{2-methoxy-5-[(E)-3-oxo-3-(3,4,5-trimethoxyphenyl)-1-propenyl]phenoxy}acetamide (9j) 
       [0184]    To a solution of 6-(trifluoromethoxy)-2-aminobenzothiazole (234 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{2-methoxy-5-[(E)-3-oxo-3-(3-(3,4,5-trimethoxy phenyl)-1-propenyl]phenoxy}acetic acid (2) (402 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (9j) (498 mg, 80% yield) 
         [0185]      1 H NMR (CDCl 3 ): □□10.62 (br s, 1H), 7.77 (d, 1H, J=9.0 Hz), 7.66-7.73 (m, 2H), 7.27-7.39 (m, 3H), 7.24 (d, 1H, J=15.1 Hz), 7.22 (s, 2H), 6.98 (d, 1H, J=8.3 Hz), 4.83 (s, 2H), 4.07 (s, 3H), 3.95 (s, 6H), 3.91 (s, 3H); ESIMS: 619 (M+1) + . 
       Example 9 
     N1-(1,3-benzothiazol-2-yl)-2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10a) 
       [0186]    To a solution of 2-aminobenzothiazole (359.37 ma, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 ma, 0.1 mmol). Then added 2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetic acid (3) (458 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (10a) (472 mg, 80% yield) 
         [0187]      1 H NMR (CDCl 3 ): δ 7.73-7.81 (m, 2H), 7.40 (t, 1H), 7.29 (d, 1H, J=7.3 Hz), 6.92-6.97 (m, 1H), 6.85-6.91 (m, 4H), 5.44-5.53 (dd, 1H, J=11.7, 4.5 Hz), 4.69 (s, 2H), 3.99 (s, 3H), 3.90 (s, 6H), 3.86 (s, 3H), 3.64-3.76 (dd, 1H, J=11.8, 17.3 Hz), 3.04-3.14 (dd, 1H, J=17.3, 4.5 Hz), 2.40 (s, 3H); ESIMS: 591 (M+1) + . 
       Example 10 
     N1-[6-(trifluoromethyl)-1,3-benzothiazol-2-yl]-2-{5-[1-acetyl-3-(3,4,5-trimethoxy phenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10i) 
       [0188]    To a solution of 6-(trifluoromethyl)-2-aminobenzothiazole (218 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetic acid (3) (458 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (10i) (528 mg, 80% yield). 
         [0189]      1 H NMR (CDCl 3 ): δ 10.82 (br s, 1H), 8.11 (s, 1H), 7.88 (d, 1H, J=7.9 Hz), 7.67-7.70 (m, 1H), 6.98-7.02 (dd, 1H, J=7.9, 1.6 Hz), 6.96 (s, 2H), 6.90-6.94 (m, 2H), 5.51-5.56 (dd, 1H, J=11.9, 3.9 Hz), 4.79 (s, 2H), 3.99 (s, 3H), 3.91 (s, 6H), 3.89 (s, 3H), 3.71-3.79 (dd, 1H, J=11.9, 17.5 Hz), 3.10-3.15 (dd, 1H, J=17.5, 4.7 Hz), 2.43 (s, 3H); ESIMS: 659 (M+1) + . 
       Example 11 
     N1-[6-(trifluoromethoxy)-1,3-benzothiazol-2-yl]-2-{5-[1-acetyl-3-(3,4,5-trimethoxy phenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetamide (10j) 
       [0190]    To a solution of 6-(trifluoromethoxy)-2-aminobenzothiazole (234 mg, 1.0 mmol) in dichloromethane (20 mL) was added 1-Ethyl-3-(3-Dimethylaminopropyl)carbodiimide (EDC) (191 mg, 1.0 mmol) and 1-hydroxy-1,2,3-benzotriazole (HOBt) (13.5 mg, 0.1 mmol). Then added 2-{5-[1-acetyl-3-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1H-5-pyrazolyl]-2-methoxyphenoxy}acetic acid (3) (458 mg, 0.1 mmol) and the reaction mixture was stirred at a temperature of 25° C. for 24 h and the reaction was monitored by TLC. Then to this water is added and extracted with dichloromethane. The solvent was evaporated under vacuum to afford the crude product. This was further purified by column chromatography using ethyl acetate and hexane as solvent system to obtain the pure product (10j) (531 mg, 80% yield). 
         [0191]      1 H NMR (CDCl 3 ): δ 10.71 (br s, 1H), 7.79 (d, 1H, J=8.3 Hz), 7.69 (d, 1H, J=1.5 Hz), 7.29-7.34 (dd, 1H, J=9.0, 1.5 Hz), 6.98-7.02 (dd, 1H, J=8.3, 1.5 Hz), 6.96 (s, 2H), 6.89-6.94 (m, 2H), 5.50-5.58 (dd, 1H, J=11.3, 4.5 Hz), 4.77 (s, 2H), 3.98 (s, 3H), 3.91 (s, 6H), 3.90 (s, 3H), 3.69-3.81 (dd, 1H, J=18.1, 12.0 Hz), 3.08-3.17 (dd, 1H, J=17.3, 4.5 Hz), 2.43 (s, 3H); ESIMS: 675 (M+1) + . 
       Biological Activity 
       [0192]    The in vitro anticancer activity studies for these amidobenzothiazoles were carried out at the National Cancer Institute, Maryland, USA. 
       In Vitro Cytotoxicity 
       [0193]    The amidobenzothiazoles have been tested against sixty human tumor cell lines derived from nine cancer types (leukemia cancer cell line, non-small cell lung cancer cell line, colon cancer cell line, CNS cancer cell line, melanoma cancer cell line, ovarian cancer cell line, renal cancer cell line, prostate cancer cell line and breast cancer cell lines). For these compounds results are expressed in GI50 values of that particular cancer cell at micro molar (μM) concentration as per NCI protocol. The compounds 8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j, and 10i were evaluated for in vitro anticancer activity against sixty human tumor cells derived from nine cancer types (leukemia, non-small cell lung cancer, colon cancer, CNS cancer, melanoma cancer, ovarian cancer, renal cancer, prostate cancer and breast cancer) at concentration of μM and the results are shown in Tables 2. 
         [0194]    The compounds 8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i exhibited an interesting profile of anti cancer activity against various cancer cell lines. 
         [0000]    
       
         
               
             
               
               
             
               
               
               
               
               
               
               
               
               
               
               
               
             
               
               
               
               
               
               
               
               
               
               
               
               
             
           
               
                 TABLE 2 
               
             
             
               
                   
               
               
                 In vitro cytotoxicity of compounds 8a, 8e, 8g, 8i, 8j, 9a, 9e, 9g, 9i, 9j and 10i against sixty human cancer cell lines. 
               
             
          
           
               
                 Panel/Cell 
                 GI50 values (μM conc.) 
               
             
          
           
               
                 Line 
                 8a 
                 8e 
                 8g 
                 8i 
                 8j 
                 9a 
                 9e 
                 9g 
                 9i 
                 9j 
                 10i 
               
               
                   
               
             
          
           
               
                 Leukemia 
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
                   
               
               
                 CCRF-CEM 
                 0.078 
                 3.70 
                 3.87 
                 4.27 
                 4.12 
                 2.09 
                 5.73 
                 3.55 
                 3.37 
                 2.5 
                 — 
               
               
                 HL-60(TB) 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
                 — 
               
               
                 K-562 
                 0.042 
                 3.62 
                 3.6 
                 3.3 
                 3.43 
                 0.44 
                 4.32 
                 3.52 
                 3.67 
                 0.43 
                 — 
               
               
                 MOLT-4 
                 0.34 
                 3.07 
                 3.87 
                 3.75 
                 4.21 
                 3.03 
                 29.9 
                 3.5 
                 4.31 
                 2.89 
                 — 
               
               
                 RPMI-8226 
                 0.15 
                 6.36 
                 5.43 
                 5.48 
                 5.83 
                 1.09 
                 7.35 
                 3.02 
                 3.84 
                 2.02 
                 2.21 
               
               
                 SR 
                 0.037 
                 2.19 
                 3.69 
                 3.35 
                 3.55 
                 0.38 
                 3.17 
                 2.53 
                 0.85 
                 0.39 
                 — 
               
               
                 Non-small cell 
               
               
                 lung 
               
               
                 A549/ATCC 
                 0.34 
                 5.99 
                 5.19 
                 4.46 
                 6 
                 2.63 
                 23.2 
                 11.7 
                 14.3 
                 1.99 
                 2.16 
               
               
                 EKVX 
                 0.038 
                 5.72 
                 5.11 
                 6.25 
                 7.89 
                 5.91 
                 38.1 
                 50.3 
                 30.3 
                 5.11 
                 4.1 
               
               
                 HOP-62 
                 — 
                 5.70 
                 23 
                 5.22 
                 7.09 
                 6.11 
                 11.7 
                 4.11 
                 6.57 
                 2.12 
                 2.2 
               
               
                 HOP-92 
                 0.039 
                 5.73 
                 6.28 
                 2.88 
                 2.74 
                 1.33 
                 2.39 
                 2.62 
                 4.1 
                 2.14 
                 1.7 
               
               
                 NCI-H226 
                 0.27 
                 5.60 
                 4.51 
                 3.17 
                 4.3 
                 2.77 
                 21.1 
                 32.5 
                 21.5 
                 3.35 
                 2.22 
               
               
                 NCI-H23 
                 0.11 
                 4.26 
                 3.91 
                 3.9 
                 4.39 
                 3.4 
                 11 
                 5.06 
                 3.68 
                 2.15 
                 3.76 
               
               
                 NCI-H322M 
                 — 
                 &gt;100 
                 &gt;100 
                 5.38 
                 &gt;100 
                 4.26 
                 38.1 
                 7.16 
                 6.73 
                 2.77 
                 3.67 
               
               
                 NCI-H460 
                 0.052 
                 4.36 
                 3.73 
                 3.55 
                 4.11 
                 2.64 
                 13.5 
                 3.32 
                 4.06 
                 2.43 
                 — 
               
               
                 NCI-H522 
                 0.079 
                 2.92 
                 3.09 
                 2.89 
                 3.16 
                 1.32 
                 3.2 
                 2.16 
                 2 
                 0.67 
                 2.71 
               
               
                 Colon 
               
               
                 COLO-205 
                 2.83 
                 7.78 
                 3.89 
                 17.1 
                 43.3 
                 5.47 
                 26.8 
                 58.5 
                 37.7 
                 6.37 
                 3.94 
               
               
                 HCC-2998 
                 0.37 
                 &gt;100 
                 7.34 
                 4.23 
                 17.1 
                 2.14 
                 33 
                 19.3 
                 21.3 
                 6.18 
                 &gt;100 
               
               
                 HCT-116 
                 0.046 
                 4.48 
                 3.7 
                 3.29 
                 3.92 
                 2.88 
                 15.7 
                 3.98 
                 3.83 
                 1.43 
                 2.39 
               
               
                 HCT-15 
                 0.048 
                 8.19 
                 2.89 
                 3.24 
                 3.23 
                 0.49 
                 3.96 
                 3.34 
                 2.68 
                 0.4 
                 9.26 
               
               
                 HT29 
                 3.16 
                 9.63 
                 3.34 
                 14.9 
                 &gt;100 
                 3.49 
                 94.8 
                 32.4 
                 21.5 
                 3.66 
                 — 
               
               
                 KM12 
                 0.058 
                 4.78 
                 3.12 
                 3.14 
                 4.48 
                 0.36 
                 2.97 
                 2.4 
                 1.77 
                 1.51 
                 — 
               
               
                 SW-620 
                 — 
                 65 
                 5.1 
                 4.65 
                 5.65 
                 0.62 
                 3.84 
                 4.07 
                 3.82 
                 1.08 
                 &gt;100 
               
               
                 CNS 
               
               
                 SF-268 
                 0.18 
                 7.23 
                 4.31 
                 3.85 
                 6.01 
                 0.95 
                 3.78 
                 4.16 
                 3.28 
                 1.2 
                 3.84 
               
               
                 SF-295 
                 0.22 
                 4.29 
                 1.84 
                 3.36 
                 3.7 
                 3.41 
                 18.8 
                 6.68 
                 8.87 
                 2.21 
                 3.06 
               
               
                 SF-539 
                 0.045 
                 4.51 
                 2.84 
                 2.66 
                 2.28 
                 0.34 
                 2.49 
                 2.17 
                 2.1 
                 0.29 
                 1.75 
               
               
                 SNB-19 
                 — 
                 &gt;100 
                 6.3 
                 5.03 
                 7.08 
                 2.81 
                 17.3 
                 5.61 
                 6.01 
                 1.58 
                 11 
               
               
                 SNB-75 
                 0.046 
                 4.39 
                 1.91 
                 1.58 
                 1.56 
                 0.53 
                 1.67 
                 2.04 
                 2.2 
                 0.34 
                 1.55 
               
               
                 U251 
                 0.048 
                 4.33 
                 4 
                 3.67 
                 3.37 
                 0.96 
                 6.08 
                 3.08 
                 3.27 
                 0.7 
                 3.08 
               
               
                 Melanoma 
               
               
                 LOX IMVI 
                 0.067 
                 3.23 
                 4.17 
                 4.01 
                 4.77 
                 0.52 
                 3.37 
                 2.59 
                 2.88 
                 0.47 
                 3.36 
               
               
                 MALME-3M 
                 1.99 
                 5.22 
                 &gt;100 
                 &gt;100 
                 — 
                 6.42 
                 27.7 
                 9.62 
                 8.75 
                 2.69 
                 6.44 
               
               
                 M14 
                 0.072 
                 6.82 
                 4.33 
                 3.58 
                 4.36 
                 3.29 
                 10.7 
                 3.28 
                 3.31 
                 1.72 
                 — 
               
               
                 MDA-MB-435 
                 0.019 
                 0.33 
                 1.16 
                 1.84 
                 1.93 
                 0.3 
                 1.93 
                 1.51 
                 1.16 
                 0.3 
                 3.08 
               
               
                 SK-MEL-2 
                 0.18 
                 8.46 
                 4.07 
                 3.98 
                 3.29 
                 5.39 
                 100 
                 24.2 
                 30 
                 4.97 
                 — 
               
               
                 SK-MEL-28 
                 — 
                 &gt;100 
                 4.41 
                 3 
                 4.57 
                 4.61 
                 24.1 
                 14.4 
                 9.47 
                 3.31 
                 3.56 
               
               
                 SK-MEL-5 
                 0.036 
                 1.76 
                 2.68 
                 2.84 
                 3.26 
                 1.76 
                 4.49 
                 4.56 
                 2.88 
                 2.03 
                 — 
               
               
                 UACC-257 
                 11 
                 8.69 
                 63 
                 40 
                 89.2 
                 1.37 
                 73.2 
                 20.4 
                 49.5 
                 8.08 
                 3.77 
               
               
                 UACC-62 
                 0.063 
                 4.05 
                 5.93 
                 3.9 
                 5.11 
                 7.87 
                 33.6 
                 14.5 
                 22.7 
                 9.52 
               
               
                 Ovarian 
               
               
                 IGROV1 
                 0.21 
                 4.17 
                 7 
                 4.48 
                 5.64 
                 3.6 
                 16.2 
                 7.73 
                 15.6 
                 2.54 
                 5.3 
               
               
                 OVCAR-3 
                 0.043 
                 9.99 
                 2.17 
                 2.11 
                 3.37 
                 0.48 
                 3.4 
                 2.6 
                 1.95 
                 1.52 
                 1.84 
               
               
                 OVCAR-4 
                 0.37 
                 7.30 
                 5.31 
                 4.66 
                 5.34 
                 3.2 
                 14.7 
                 11.2 
                 4.37 
                 2.07 
                 2.9 
               
               
                 OVCAR-5 
                 — 
                 &gt;100 
                 5.89 
                 5.98 
                 3.12 
                 3.54 
                 91.6 
                 71.7 
                 38.9 
                 4.76 
                 28.2 
               
               
                 OVCAR-8 
                 0.25 
                 7.15 
                 5.28 
                 3.86 
                 5 
                 2.77 
                 10.2 
                 3.49 
                 3.85 
                 1.54 
                 3.36 
               
               
                 NCI/ADR- 
                 0.033 
                 2.55 
                 2.3 
                 2.12 
                 2.7 
                 0.48 
                 2.43 
                 1.89 
                 1.73 
                 0.49 
                 3.13 
               
               
                 RES 
               
               
                 SK-OV-3 
                 0.34 
                 8 
                 4.69 
                 3.29 
                 8.42 
                 2.54 
                 15.2 
                 7.32 
                 5.08 
                 2.16 
                 5.75 
               
               
                 Renal 
               
               
                 786-0 
                 7.3 
                 7.12 
                 7.52 
                 6.96 
                 54.3 
                 4.12 
                 24.7 
                 19.4 
                 24.6 
                 2.26 
                 3.58 
               
               
                 A498 
                 0.36 
                 6.25 
                 3.5 
                 2.81 
                 3.61 
                 22.6 
                 100 
                 100 
                 100 
                 7.4 
                 2.78 
               
               
                 ACHN 
                 0.093 
                 3.33 
                 7.77 
                 4.82 
                 8.31 
                 3.46 
                 12.4 
                 4.94 
                 7.48 
                 1.62 
                 2.48 
               
               
                 CAKI-1 
                 0.41 
                 2.78 
                 3.2 
                 3.1 
                 4.6 
                 3.78 
                 30.7 
                 25.1 
                 10.9 
                 2.2 
                 2.17 
               
               
                 RXF 393 
                 0.05 
                 6.29 
                 2.5 
                 2.27 
                 2.65 
                 1.83 
                 8.5 
                 2.37 
                 2.6 
                 1.58 
                 2.09 
               
               
                 SN12C 
                 0.37 
                 4.61 
                 5.75 
                 4.43 
                 6.42 
                 3.02 
                 17.4 
                 5.19 
                 5.41 
                 1.74 
                 3.31 
               
               
                 TK-10 
                 — 
                 9.89 
                 7.54 
                 7.03 
                 18.6 
                 3.3 
                 20.9 
                 16.4 
                 15.6 
                 2.08 
                 2.85 
               
               
                 UO-31 
                 0.58 
                 2.56 
                 4.31 
                 3.59 
                 4.37 
                 3.07 
                 6.83 
                 5.31 
                 7.8 
                 1.61 
                 1.93 
               
               
                 Prostate 
               
               
                 PC-3 
                 0.18 
                 6.74 
                 4.45 
                 4.32 
                 5.12 
                 3.63 
                 22.9 
                 12.2 
                 12 
                 3.14 
                 2.92 
               
               
                 DU-145 
                 0.1 
                 8.97 
                 2.04 
                 2.51 
                 4.11 
                 1.94 
                 4.05 
                 2.49 
                 2.62 
                 1.56 
                 1.82 
               
               
                 Breast 
               
               
                 MCF7 
                 0.051 
                 2.3 
                 2.88 
                 3.16 
                 2.89 
                 1.05 
                 3.7 
                 3.02 
                 3.05 
                 1.32 
                 4.02 
               
               
                 MDA-MB- 
                 0.19 
                 9.34 
                 5.4 
                 3.38 
                 5.16 
                 2.69 
                 12.6 
                 5.82 
                 7.14 
                 2.01 
                 3.11 
               
               
                 231/ATCC 
               
               
                 HS 578T 
                 — 
                 &gt;100 
                 4.15 
                 4.18 
                 4.33 
                 4.75 
                 10.5 
                 3.72 
                 4.81 
                 3.08 
                 2.48 
               
               
                 BT-549 
                 0.41 
                 16.7 
                 21.2 
                 5.23 
                 10.5 
                 4.82 
                 4.82 
                 8.38 
                 11.2 
                 2.71 
                 3.55 
               
               
                 T-47D 
                 1.0 
                 3.39 
                 4.03 
                 4.79 
                 3.95 
                 4.97 
                 58.5 
                 14.7 
                 15 
                 3.08 
                 2.75 
               
               
                 MDA-MB-468 
                 0.1 
                 3.68 
                 2.29 
                 2.16 
                 2.3 
                 2.3 
                 13.1 
                 10.5 
                 13.5 
                 3.52 
                 6.12 
               
               
                   
               
             
          
         
       
     
       ADVANTAGES OF THE INVENTION 
       [0000]    
       
         
           
             1. The present invention provides amidobenzothiazole of general formula A useful as anticancer agents. 
             2. It also provides a process for the preparation of amidobenzothiazole of general formula A.